All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The mm Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mm Hub cannot guarantee the accuracy of translated content. The mm and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Johnson & Johnson, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

Prof. Mohamad Mohty | EBMT 2018 | Role of double auto-transplant in Multiple Myeloma

By Fiona Chaplin

Share:

Featured:

Mohamad MohtyMohamad Mohty

Mar 22, 2018


44th European Society for Blood and Marrow Transplantation (EBMT) Annual Meeting, 18–21 Mar 2018, Lisbon, PT.

Professor Mohamad Mohty (Hospital Saint-Antoine and University Pierre & Marie Curie, Paris, FR): Role of double auto-transplant in Multiple Myeloma

Role of double auto-transplant in Multiple Myeloma